Durable complete response of advanced hepatocellular carcinoma using cannabis oil: a report of two cases

Pieter F. van den Berg; Frans van der Heide; Simeon J.S. Ruiter; Jules J.G. Slangen; Derk Jan A. de Groot; Evert van den Broek; Frederik J.H. Hoogwater; Maarten W. Nijkamp

doi:10.1186/s42238-025-00353-0

journal article Open Access Nov 24, 2025

Durable complete response of advanced hepatocellular carcinoma using cannabis oil: a report of two cases

Pieter F. van den Berg Frans van der Heide Simeon J.S. Ruiter

Jules J.G. Slangen Derk Jan A. de Groot Evert van den Broek Frederik J.H. Hoogwater Maarten W. Nijkamp

Journal of Cannabis Research Vol. 7 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1186/s42238-025-00353-0

Topics

No keywords indexed for this article. Browse by subject →

References

18

[1]

Costentin CE, Mourad A, Lahmek P, Causse X, Pariente A, Hagège H, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study. Cancer. 2018;124(9):1964–72. 10.1002/cncr.31215

[2]

Esmaeli M, Dehghanpour Dehabadi M. Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence. Cancer Cell Int. 2025;25(1):215. 10.1186/s12935-025-03870-3

[3]

Hepatocellular carcinoma

Alejandro Forner, Maria Reig, Jordi Bruix

The Lancet 2018 10.1016/s0140-6736(18)30010-2

[4]

Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745–55. 10.1038/nrc1188

[5]

Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018;1(1):65–72. 10.1159/000489287

[6]

Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019;176(10):1384–94. 10.1111/bph.14426

[7]

Oelen Y, Revenberg S, de Vos-Geelen J, van Geel R, Schoenmaekers J, van den Beuken-Everdingen M, et al. Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands. J Cancer Res Clin Oncol. 2023;149(5):1863–72. 10.1007/s00432-022-04085-z

[8]

Oquiñena S, Guillen-Grima F, Iñarrairaegui M, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol. 2009;21(3):254–7. 10.1097/meg.0b013e328324b6a2

[9]

Pellerito O, Calvaruso G, Portanova P, De Blasio A, Santulli A, Vento R, et al. The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol Pharmacol. 2010;77(5):854–63. 10.1124/mol.109.062257

[10]

Rao M, Chen D, Zhan P, Jiang J. MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct. 2019;14(1):9. 10.1186/s13062-019-0241-1

[11]

Shah D, Shah D, Mohamed Y, Rosas D, Moffitt A, Haynes TH, et al. In. Anti-Tumor effects of cannabinoids in Brain, Lung, Breast, Prostate, Colorectal, and pancreatic cancers. In: Zeine R, Teasdale B, editors. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. IGI Global Scientific Publishing; 2023. p. 119–46. https://doi.org/10.4018/978-1-6684-5652-1.ch005. 10.4018/978-1-6684-5652-1.ch005

[12]

van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, Jansen PLM, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers. Eur J Gastroenterol Hepatol. 2016;28(3):352–9. 10.1097/meg.0000000000000527

[13]

Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18(7):1099–111. 10.1038/cdd.2011.32

[14]

Vara D, Morell C, Rodríguez-Henche N, Diaz-Laviada I. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis. 2013;4(5):e618–618. 10.1038/cddis.2013.141

[15]

Woerdenbag HJ, Olinga P, Kok EA, Brugman DAP, van Ark UF, Ramcharan AS, et al. Potential, limitations and risks of cannabis-derived products in cancer treatment. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15072119. 10.3390/cancers15072119

[16]

Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31–8. 10.1016/j.cancergencyto.2006.06.014

[17]

XU D, WANG J, ZHOU Z, HE Z, Cannabinoid ZHAOQ. 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells. Mol Med Rep. 2015;WIN55(6):7963–70. 10.3892/mmr.2015.4477

[18]

Yang J, Tian Y, Zheng R, Li L, Qiu F. Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma. Oncol Lett. 2019. 10.3892/ol.2019.10399

Metrics

1

Citations

18

References

Details

Published: Nov 24, 2025
Vol/Issue: 7(1)
License: View

Authors

P

Pieter F. van den Berg

Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Frederik J.H. Hoogwater

M

Maarten W. Nijkamp

Cite This Article

Pieter F. van den Berg, Frans van der Heide, Simeon J.S. Ruiter, et al. (2025). Durable complete response of advanced hepatocellular carcinoma using cannabis oil: a report of two cases. Journal of Cannabis Research, 7(1). https://doi.org/10.1186/s42238-025-00353-0

Durable complete response of advanced hepatocellular carcinoma using cannabis oil: a report of two cases

You May Also Like